MARIZYME INC. MRZM overview

JUPITER, FL, April 16, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Marizyme, Inc. ("Marizyme", OTCQB: MRZM) announces today a Co-Development Agreement (the “Agreement”) with Qualigen Therapeutics, Inc. (“Qualigen”) (NASDAQ: QLGN ) to advance the commercialization of Marizyme’s first-in-class FDA cleared product, DuraGraft™. DuraGraft™ was granted a De Novo – FDA Clearance on October 4, 2023, from the U.S. Food and Drug Administration (FDA). DuraGraft™ is labeled for use as a...

Marizyme, Inc. Marizyme CEO Delivers Business Update 23-Oct-2023 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. Marizyme CEO Delivers Business Update JUPITER, FL via NewMediaWire - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel: “I am very pleased to bring you an update on the Company’s FDA...

JUPITER, FL, Oct. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), today provided the following business update to the stockholders and the investing public from the Company’s Chief Executive Officer, David Barthel: “I am very pleased to bring you an update on the Company’s FDA Clearance for DuraGraft™ as well as Marizyme’s business priorities for 2024. “After our last business update on May 3, 2023, the Company has been...

VANCOUVER, BC / ACCESSWIRE / October 13, 2023 / Marizyme, Inc. (OTCQB:MRZM), a global multi-technology biomedical company dedicated to the accelerated development and commercialization of medical technologies that improve patient health outcomes, is featured in today's video by InvestmentPitch Media. The company was recently granted a de novo from the U.S. Food and Drug Administration for its first-in-class product, DuraGraft™. With the granting of this de novo, DuraGraft is the first and only...

VANCOUVER, BC / ACCESSWIRE / October 6, 2023 / The Watchlist by The Market Herald has announced the release of new interviews with FPX Nickel, Pelangio Exploration, Nicola Mining, and Max Resource discussing their latest news. The Watchlist by The Market Herald provides investors with a quick snapshot of what they need to know about the company's latest press release through exclusive insights and interviews with company executives. Marizyme, Inc. Announces FDA Clearance for Flagship Product,...

Marizyme, Inc. Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft™ 06-Oct-2023 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. Marizyme, Inc. Announces FDA Clearance for Flagship Product, DuraGraft ™ DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries JUPITER, FL - via NewMediaWire - Marizyme, Inc. (OTCQB:MRZM)...

DuraGraft is the first and only FDA cleared medical device for use as an intra-operative vascular conduit storage and flushing solution used during CABG surgeries JUPITER, FL, Oct. 06, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - Marizyme, Inc. (OTCQB:MRZM) (“Marizyme” or the “Company”), a global medical technology company focused on the development of products to address unmet clinical needs, today announced that it was granted a de novo from the U.S. Food and Drug Administration (FDA)...

Marizyme, Inc. Marizyme, Inc.: Marizyme Announces IP Developments for DuraGraft® and its Pipeline of Products 10-May-2023 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Marizyme Announces IP Developments for DuraGraft® and its Pipeline of Products JUPITER, FL, May 10, 2023 Marizyme, Inc. ("Marizyme" or the "Company") (OTCQB: MRZM), a multi-technology biomedical company focused on the accelerated development and commercialization of medical technologies...